Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Oct 25;18(5):588.
doi: 10.1186/s13054-014-0588-8.

Argatroban Versus Lepirudin in Critically Ill Patients (ALicia): A Randomized Controlled Trial

Free PMC article
Randomized Controlled Trial

Argatroban Versus Lepirudin in Critically Ill Patients (ALicia): A Randomized Controlled Trial

Tanja A Treschan et al. Crit Care. .
Free PMC article

Abstract

Introduction: Critically ill patients often require renal replacement therapy accompanied by thrombocytopenia. Thrombocytopenia during heparin anticoagulation may be due to heparin-induced thrombocytopenia with need for alternative anticoagulation. Therefore, we compared argatroban and lepirudin in critically ill surgical patients.

Methods: Following institutional review board approval and written informed consent, critically ill surgical patients more than or equal to 18 years with suspected heparin-induced thrombocytopenia, were randomly assigned to receive double-blind argatroban or lepirudin anticoagulation targeting an activated Partial Thromboplastin Time (aPTT) of 1.5 to 2 times baseline. In patients requiring continuous renal replacement therapy we compared the life-time of hemodialysis filters. We evaluated in all patients the incidence of bleeding and thrombembolic events.

Results: We identified 66 patients with suspected heparin-induced thrombocytopenia, including 28 requiring renal replacement therapy. Mean filter lifetimes did not differ between groups (argatroban 32 ± 25 hours (n = 12) versus lepirudin 27 ± 21 hours (n = 16), mean difference 5 hours, 95% CI -13 to 23, P = 0.227). Among all 66 patients, relevant bleeding occurred in four argatroban- versus eleven lepirudin-patients (OR 3.9, 95% CI 1.1 to 14.0, P = 0.040). In the argatroban-group, three thromboembolic events occurred compared to two in the lepirudin group (OR 0.7, 95% CI 0.1 to 4.4, P = 0.639). The incidence of confirmed heparin-induced thrombocytopenia was 23% (n = 15) in our study population.

Conclusions: This first randomized controlled double-blind trial comparing two direct thrombin inhibitors showed comparable effectiveness for renal replacement therapy, but suggests fewer bleeds in surgical patients with argatroban anticoagulation.

Trial registration: Clinical Trials.gov NCT00798525. Registered 25 November 2008.

Figures

Figure 1
Figure 1
Trial flow chart. Data are presented as mean ± SD, n = number of patients, sec = seconds. SD, standard deviation.
Figure 2
Figure 2
Kaplan-Meier analyses of time till filter clotting.

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles

References

    1. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schünemann HJ. Executive summary: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:7S–47S. doi: 10.1378/chest.1412S3. - DOI - PMC - PubMed
    1. Arnold DM, Donahoe L, Clarke FJ, Tkaczyk AJ, Heels-Ansdell D, Zytaruk N, Cook R, Webert KE, McDonald E, Cook DJ. Bleeding during critical illness: a prospective cohort study using a new measurement tool. Clin Invest Med. 2007;30:E93–E102. - PubMed
    1. Franchini M. Heparin-induced thrombocytopenia: an update. Thromb J. 2005;3:14. doi: 10.1186/1477-9560-3-14. - DOI - PMC - PubMed
    1. Warkentin TE. Heparin-induced thrombocytopenia in the ICU: a transatlantic perspective. Chest. 2012;142:815–816. doi: 10.1378/chest.12-0979. - DOI - PubMed
    1. Trehel-Tursis V, Louvain-Quintard V, Zarrouki Y, Imbert A, Doubine S, Stéphan F. Clinical and biologic features of patients suspected or confirmed to have heparin-induced thrombocytopenia in a cardiothoracic surgical ICU. Chest. 2012;142:837–844. doi: 10.1378/chest.11-3074. - DOI - PubMed

Publication types

MeSH terms

Associated data

Feedback